Today’s Research Reports on Stocks to Watch: AcelRx Pharmaceuticals and Sangamo Therapeutics
Sangamo shares catapulted on Friday after the company announced the FDA has granted Fast Track designation to its clinical stage in vivo genome editing product candidates, SB-318 and SB-913. Shares of AcelRx also saw big gains after the stock received a $7.00 price target from Jefferies.
RDI Initiates Coverage on:
AcelRx Pharmaceuticals, Inc.
Sangamo Therapeutics, Inc.
AcelRx Pharmaceuticals, Inc. shares closed up 11.63% on Friday with staggering volume compared to usual. The big jump came after Jefferies analyst Matthew Andrews assumed coverage on the stock. Andrews has put a $7.00 price target on AcelRx which had traders pretty excited. From Friday’s closing price it would represent upside of over 190%. Shares closed at $2.40 on Friday. According to Andrews, the company’s DSUVIA, which is for the treatment of moderate to severe acute pain, will be approved on its October 12th, 2017 PDUFA date. Andrews said, "While the FDA under Dr. Gottlieb is focused on addressing the U.S.’s opioid crisis, we believe this will largely focus on the appropriate use and duration of chronic (not acute) opioid therapy. The CHMP’s decision on the Dsuvia MAA in Europe is expected in H1 2018, and the EMA has already approved Zalviso (a 15mcg tablet of sufentanil). We probability weight our U.S. and Europe Dsuvia estimates at 75% and 80%, respectively." Andrews also noted, "ACRX is under-valued due to potent oral opioid Dsuvia’s promise in medicallysupervised acute pain markets (~92M patients) and we see high likelihood of U.S./EU approvals in Q4’17/H1’18. Risk/reward is favorable into H1’18 with floor of ~$1.25 (no approvals) vs. $12/share (upside scenario)."
Access RDI’s AcelRx Pharmaceuticals, Inc. Research Report at:
Sangamo Therapeutics, Inc. shares closed up 6.32% on Friday with volume almost twice as high as usual. Shares also hit a new high of $10.50 during intra-day trading. The stock surged in after-hours trading on Thursday after the company announced that the FDA granted fast track expediting of marketing applications for two of Sangamo’s drugs, SB-318 and SB-913. The two drugs are intended for the treatment of rare metabolic disorders. SB-318 is intended to treat Mucapolysaccharidosis Type 1 while SB-913 is meant to treat Mucopolysaccharidosis Type II. These are two inherited genetic diseases. According to the company, they are caused by mutations in genes encoding enzymes that break down unwanted substances in cells. Lack of these enzymes leads to the toxic build-up of these substances. The resulting cell damage can lead to serious health problems. Both drugs have already received Orphan Drug and Rare Pediatric Disease designations from the FDA.
Access RDI’s Sangamo Therapeutics, Inc. Research Report at:
Our Actionable Research on AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) and Sangamo Therapeutics, Inc. (NASDAQ: SGMO) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.